Market research
ALKEM.NSE Alkem Laboratories Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 640B
- P/E ratio
- 29.94
- Analyst target
- 5948.55
- Dividend yield
- 1.0%
- Beta
- 0.29
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE540L01014
- Market cap
- 640B
- P/E ratio
- 29.94
- Analyst target
- 5948.55
- Dividend yield
- 1.0%
- Beta
- 0.29
About
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti " infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALKEM.NSE discussion.
5 years, 5 months ago
Alkem Laboratories Limited is currently in a long term uptrend where the price is trading 15.4% above its 200 day moving average.
From a valuation standpoint, the stock is 20.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Alkem Laboratories Limited's total revenue rose by 6.2% to $23B since the same quarter in the previous year.
Its net income has increased by 18.1% to $5B since the same quarter in the previous year.
Finally, its free cash flow grew by 260.3% to $8B since the same quarter in the previous year.
Based on the above factors, Alkem Laboratories Limited gets an overall score of 5/5.